HIGHBuilt-inPipeline
bel-sar
“10-K Item 1A: 'We are heavily dependent on the success of bel-sar, our only product candidate to date.'”
AURA · Concentration risk · 10-K extracted
Aura Biosciences (AURA) concentration risks
Updated
The most significant concentration Aura Biosciences discloses is bel-sar, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Aura Biosciences’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 1 disclosed concentration
HIGH1
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06Aura Biosciences' disclosed concentration risk is entirely pipeline-based: the company is heavily dependent on the success of bel-sar, its only product candidate to date. This is a high-size, structural exposure — as a clinical-stage company with a single named candidate, Aura's entire near-term commercial and clinical narrative rests on this one asset rather than being spread across a portfolio of programs. Because bel-sar is described as the company's only product candidate, there is no secondary asset disclosed to offset a clinical, regulatory, or commercial setback; every material catalyst for the company runs through this single program. With this as the sole disclosed concentration exposure and its size at the high end of the scale, it is effectively the entirety of the investment case for Aura Biosciences — trial results, regulatory interactions, and eventual commercialization prospects for bel-sar will directly determine the company's trajectory, with no diversification across products, customers, or geographies to cushion an adverse outcome. This is a textbook single-asset clinical-stage risk profile, where the concentration disclosure and the core investment thesis are one and the same.
For the engine’s reasoning on AURA’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| AURA● | Aura Biosciences, Inc. | 1 | 0 | 0 | 1 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.